Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Filaggrin antisense RNA 1 (FLG-AS1), also referenced as AL589986.2 and LINC02962, is a long non-coding RNA found in the non-protein coding portion of the genome[1]. It has been shown to promote keratinocyte proliferation and appears linked to the risk of inflammatory skin conditions like psoriasis through specific genetic polymorphisms[1]. While some aliases and database entries ambiguously associate this lncRNA or similar transcripts with cancer, there is no direct, standardized evidence supporting its function as a "DHX9 suppressive transcript" or specific relevance to cervical cancer under the names CCDST or lnc-CCDST. Its roles in cancer are unelucidated at this time, with the best-studied biological function being in skin cell proliferation regulation[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Filaggrin antisense RNA 1 (FLG-AS1) (FLG-AS1).